Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
For example, tumor necrosis factor inhibitors are quite successful in the treatment of rheumatoid arthritis (RA), Behçet's disease (BD), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) but not in that of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome (SS) and antineutrophil cytoplasmic antibody-associated vasculitis (AAV), conversely, RA shares genetic backgrounds more with SLE, SSc, SS and AAV than BD, AS and PsA.
|
29623390 |
2018 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To compare baseline disease activity and treatment effectiveness in biologic-naive patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) who initiate tumor necrosis factor inhibitor (TNFi) treatment and to study the role of potential confounders (e.g., HLA-B27 status).
|
27909080 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiRNA-5196 expression was significantly higher in patients with RA and AS before TNF-α therapy than in those following anti-TNF-α therapy and healthy controls.
|
29744553 |
2018 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of differential linkage disequilibrium with HLA-B27 subtypes suggest that B27 itself remains the primary gene for AS susceptibility, and TNFA and MICA are not involved in the pathogenesis of the disease.
|
10717805 |
2000 |
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Besides TNF, the IL-23/IL-17 axis is emerging as an important inflammatory pathway in SpA, as a SNP in the IL-23R locus has been associated with developing AS, mice overexpressing IL-23 develop SpA-like features and IL-17 blockade has been shown to be efficacious for AS patients in a phase II trial.
|
23969080 |
2014 |
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The -308.1 polymorphism in the promoter region of the tumor necrosis factor gene is associated with ankylosing spondylitis independent of HLA-B27.
|
10332976 |
1999 |
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High disease activity AS patients were treated with TNFα inhibitors for 12 weeks.
|
29546695 |
2018 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baseline and biannual radiographs were randomized with radiographs of TNF-naive AS patients and scored in chronologic order according to modified Stoke Ankylosing Spondylitis Spine Score (mSASSS).
|
27696754 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To compare patients affected by ankylosing spondylitis (AS) treated with anti-TNF-α for two years with controls in terms of Achilles tendon stiffness, ultrasound structure and thickness.
|
31471416 |
2020 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The tmTNFalpha-transgenic/TNFalpha-KO mice were born with crinkled tails and spinal deformities similar to those in ankylosing spondylitis.
|
16947419 |
2006 |
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that TNF gene promoter polymorphisms at positions -238 and -308 could have a small influence on AS susceptibility and prognosis.
|
19758203 |
2009 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
|
29335342 |
2018 |
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Incubation of AS and control PBMC with phytohaemagglutinin (PHA) led to upregulation of TGFbeta1, interleukin-10, tumour necrosis factor-alpha (TNFalpha) and interferon-gamma (IFNgamma) assessed by ELISA.
|
15479754 |
2005 |
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using the Ankylosing Spondylitis Disease Activity Score (ASDAS), we assessed the prevalence of ID in ax-SpA patients treated with TNFα inhibitors (TNFi).
|
28880727 |
2018 |
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicated that HDAC3 was involved in the regulation of the underlying molecular mechanism of AS by forming a negative feedback loop with miR-130a and enhancement of TNF-1α expression.
|
26531724 |
2016 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Improved knowledge of the immune/inflammatory pathways, which characterise the pathophysiology of rheumatoid arthritis (RA) and seronegative spondyloarthropathies (SpA), such as ankylosing spondylitis (AS) and psoriatic arthritis (PsA), have provided the link between inflammation and bone loss, via a complex network of bone cells, T and B cells, pro-inflammatory cytokines such as TNF-α, IL1, IL6, IL17, IL23, costimulator molecules, signalling pathways including both RANKL/RANK/OPG and Wnt signallings.
|
30557124 |
2019 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although it has been clear for twenty-five years that TNF plays a major role in RA and AS, two major questions remain unanswered: (1) What mechanism underlies the loss of control of TNF levels in patients?
|
26321488 |
2016 |
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ORs of various comparisons indicate that there is no association between TNF-α -238, -308 polymorphisms and AS susceptibility in the overall population and in the subgroup of Asian and non-Asian descent.
|
22661255 |
2013 |
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, the IL-10-819 C/T and TNF-α-857 C/T polymorphisms also confer susceptibility to AS, especially in Asian population.
|
30322951 |
2018 |
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No relationship was found between TNF-alpha promoter 238 polymorphisms and AS in HLA-b27+ population.
|
20535510 |
2010 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both diseases are mediated in part by TNF, since anti-TNF therapies have proved effective in both AS and RA.
|
19822042 |
2010 |
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
More importantly, the TIPE2 mRNA expression levels were negatively correlated with TNF-α, hsCRP and bath ankylosing spondylitis disease activity index (BASDAI) (r=-0.3574, P=0.0159; r=-0.3174, P=0.0336; r=-0.6000, P<0.0001; respectively) in the AS patients.
|
27816498 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Meanwhile, it seems that TNF inhibitors in ankylosing spondylitis may present a better safety profile than we thought.
|
31172410 |
2019 |
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the influence of patient characteristics on the course of spinal radiographic progression in a large prospective longitudinal cohort study of ankylosing spondylitis (AS) patients treated long-term with TNF-α inhibitors.
|
28640818 |
2017 |
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum TNF-α level was lower in patients with AS (151 pg/ml) than in controls (263 pg/ml), because more patients with AS had undetectable serum TNF-α (66 vs 25%, p < 0.001).
|
25028373 |
2014 |